Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain - PubMed (original) (raw)
Comment
Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain
P H Kussie et al. Science. 1996.
Abstract
The MDM2 oncoprotein is a cellular inhibitor of the p53 tumor suppressor in that it can bind the transactivation domain of p53 and downregulate its ability to activate transcription. In certain cancers, MDM2 amplification is a common event and contributes to the inactivation of p53. The crystal structure of the 109-residue amino-terminal domain of MDM2 bound to a 15-residue transactivation domain peptide of p53 revealed that MDM2 has a deep hydrophobic cleft on which the p53 peptide binds as an amphipathic alpha helix. The interface relies on the steric complementarity between the MDM2 cleft and the hydrophobic face of the p53 alpha helix and, in particular, on a triad of p53 amino acids-Phe19, Trp23, and Leu26-which insert deep into the MDM2 cleft. These same p53 residues are also involved in transactivation, supporting the hypothesis that MDM2 inactivates p53 by concealing its transactivation domain. The structure also suggests that the amphipathic alpha helix may be a common structural motif in the binding of a diverse family of transactivation factors to the TATA-binding protein-associated factors.
Comment on
- Filling in the blanks in the p53 protein structure.
Pennisi E. Pennisi E. Science. 1996 Nov 8;274(5289):921-2. doi: 10.1126/science.274.5289.921. Science. 1996. PMID: 8966571 No abstract available.
Similar articles
- Structure of the human Mdmx protein bound to the p53 tumor suppressor transactivation domain.
Popowicz GM, Czarna A, Holak TA. Popowicz GM, et al. Cell Cycle. 2008 Aug;7(15):2441-3. doi: 10.4161/cc.6365. Epub 2008 May 27. Cell Cycle. 2008. PMID: 18677113 - Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
Riaz M, Ashfaq UA, Qasim M, Yasmeen E, Ul Qamar MT, Anwar F. Riaz M, et al. Anticancer Drugs. 2017 Oct;28(9):1032-1038. doi: 10.1097/CAD.0000000000000548. Anticancer Drugs. 2017. PMID: 28723868 - Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding.
Uhrinova S, Uhrin D, Powers H, Watt K, Zheleva D, Fischer P, McInnes C, Barlow PN. Uhrinova S, et al. J Mol Biol. 2005 Jul 15;350(3):587-98. doi: 10.1016/j.jmb.2005.05.010. J Mol Biol. 2005. PMID: 15953616 - P53 mdm2 inhibitors.
Khoury K, Dömling A. Khoury K, et al. Curr Pharm Des. 2012;18(30):4668-78. doi: 10.2174/138161212802651580. Curr Pharm Des. 2012. PMID: 22650254 Free PMC article. Review. - A closer view of an oncoprotein-tumor suppressor interaction.
Shair MD. Shair MD. Chem Biol. 1997 Nov;4(11):791-4. doi: 10.1016/s1074-5521(97)90112-5. Chem Biol. 1997. PMID: 9384532 Review.
Cited by
- A structure-based virtual screening identifies a novel MDM2 antagonist in the activation of the p53 signaling and inhibition of tumor growth.
Hu QY, Li L, Li YH, Zhang HB, Deng T, Liu Y, Li FT, Xiao ZX, Cao Y. Hu QY, et al. Acta Pharmacol Sin. 2024 Oct 9. doi: 10.1038/s41401-024-01394-6. Online ahead of print. Acta Pharmacol Sin. 2024. PMID: 39384887 - Insights into the Interaction Mechanisms of Peptide and Non-Peptide Inhibitors with MDM2 Using Gaussian-Accelerated Molecular Dynamics Simulations and Deep Learning.
Yang W, Wang J, Zhao L, Chen J. Yang W, et al. Molecules. 2024 Jul 18;29(14):3377. doi: 10.3390/molecules29143377. Molecules. 2024. PMID: 39064955 Free PMC article. - The Beak of Eukaryotic Ribosomes: Life, Work and Miracles.
Martín-Villanueva S, Galmozzi CV, Ruger-Herreros C, Kressler D, de la Cruz J. Martín-Villanueva S, et al. Biomolecules. 2024 Jul 22;14(7):882. doi: 10.3390/biom14070882. Biomolecules. 2024. PMID: 39062596 Free PMC article. Review. - α-Hydrazino Acid Insertion Governs Peptide Organization in Solution by Local Structure Ordering.
Kavčič L, Ilc G, Wang B, Vlahoviček-Kahlina K, Jerić I, Plavec J. Kavčič L, et al. ACS Omega. 2024 May 8;9(20):22175-22185. doi: 10.1021/acsomega.4c00804. eCollection 2024 May 21. ACS Omega. 2024. PMID: 38799301 Free PMC article. - Tumor biomarkers for diagnosis, prognosis and targeted therapy.
Zhou Y, Tao L, Qiu J, Xu J, Yang X, Zhang Y, Tian X, Guan X, Cen X, Zhao Y. Zhou Y, et al. Signal Transduct Target Ther. 2024 May 20;9(1):132. doi: 10.1038/s41392-024-01823-2. Signal Transduct Target Ther. 2024. PMID: 38763973 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous